Targeted therapeutics for pancreatitis.

Area of Science:

• Gastroenterology and Hepatology
• Molecular and Cellular Biology
• Translational Medicine

Background:

• Acute pancreatitis (AP) and chronic pancreatitis (CP) cause significant morbidity and mortality, with limited disease-modifying therapies.
• AP complications include organ failure and necrosis; recurrent AP can lead to CP, characterized by pain and pancreatic dysfunction.
• Current supportive care for AP and CP is insufficient, highlighting the need for targeted treatments.

Purpose of the Study:

• To review the mechanistic basis for potential targeted therapies in AP and CP.
• To discuss emerging therapeutic strategies and clinical pipelines for pancreatitis.
• To emphasize the importance of timing, patient stratification, and endpoints in clinical trials for pancreatitis.

Main Methods:

• Review of mechanistic studies identifying early cellular injury pathways in pancreatitis.
• Analysis of preclinical and early-phase clinical data for novel pancreatitis targets.
• Discussion of strategies for clinical trial design, including patient enrichment and outcome measures.

Main Results:

• Early therapeutic targets include Orai1 and mitochondrial pore inhibition to prevent acinar cell injury.
• Systemic inflammation targets involve NLRP3 inflammasome, neutrophil extracellular traps, and DAMPs signaling.
• Chronic pancreatitis treatments focus on targeting pancreatic stellate cells, neuroimmune sensitization, and fibrosis.

Conclusions:

• The therapeutic landscape for pancreatitis is evolving with promising mechanism-based regimens.
• Successful clinical development hinges on matching treatment timing to disease biology and patient characteristics.
• Appropriate trial designs and endpoints are crucial for demonstrating the clinical value of novel pancreatitis therapies.